Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen.

Group 1 - Novo Nordisk received a broker downgrade due to concerns over its duopoly status in diabetes and weight loss markets being threatened [1]